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Abstract 
IMPACT NHL was a multicenter, observational study in adults with non-Hodgkin lymphoma 
receiving CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) 
chemotherapy with or without rituximab. Erythropoietin-stimulating agent treatment was 
given according to routine clinical practice and physician preference. In a subanalysis, 
outcomes were evaluated in 207 patients who received darbepoetin alfa (DA). The most 
common reason (81%) for initiating DA was low/declining hemoglobin (Hb) concentration. 
Mean (±standard deviation) duration of DA exposure was 8.8±6.9 weeks (mean number of 
doses, 5.1±4.6). Overall, 23% of patients had chemotherapy and DA treatment synchronized 
more than 75% of the time. At the time of DA initiation, 67% of patients had Hb 
concentrations in the guideline-recommended range (9–11 g/dL). Of 89 patients with Hb 
concentrations <10 g/dL at DA initiation and still receiving DA 5 weeks later, 92% (Kaplan–
Meier) achieved Hb concentrations 10–12 g/dL between week 5 and end of treatment.  
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Introduction 
Hemoglobin (Hb) concentrations <8 g/dL have been reported in 13–25% of patients receiving 
CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy, with 
or without rituximab, every 14 ([±R]CHOP-14) or 21 days ([±R]CHOP-21) [1–3]. Current 
treatment guidelines – such as those of the European Organisation for Research and 
Treatment of Cancer (EORTC) [4,5] – state that treatment with an erythropoietin-stimulating 
agent (ESA) may be initiated when Hb concentrations fall to 9–11 g/dL in patients displaying 
anemia-related symptoms; the aim of ESA treatment is to restore the Hb concentration to a 
level no greater than 12 g/dL. 
Methods 
IMPACT NHL was a multicenter, observational study of neutropenia prophylaxis and 
management [6], and anemia management, in adult patients with non-Hodgkin lymphoma 
receiving (±R)CHOP chemotherapy. Anemia-related outcomes in patients receiving any ESA 
have been reported previously [7]. Overall, 22% of patients received an ESA, of whom 51% 
received darbepoetin alfa (DA), compared with 48% who received epoetin. DA has a serum 
half-life that makes less-frequent administration possible [8], and the dosing 
recommendations differ from those of epoetin-alfa and -beta in their respective Summaries of 
Product Characteristics. Therefore, data from IMPACT NHL for those patients who received 
DA were analyzed separately. 
IMPACT NHL was conducted in 14 European countries and Australia 
(www.clinicaltrials.gov: NCT00903812). Patients who had received (±R)CHOP-14 or 
(±R)CHOP-21 could be enrolled retrospectively (5–10 patients per center) or prospectively 
(10–12 patients per center). The end of the observational period was defined as the date the 
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patient completed planned chemotherapy or the date when chemotherapy was stopped. 
Details of the study design have been presented previously [6]. 
ESA treatment was given according to routine clinical practice and physician preference. 
Patients could switch to a different ESA at any time, but were categorized for analysis 
according to the first ESA they received, with data after the switch excluded from the 
analysis. The present analysis included patients who received DA (either every 7 days or 21 
days) as their first ESA. 
Patients were adults (age ≥18 years) diagnosed with any histologic type of NHL. All patients 
were planned to receive at least three 14- or 21-day cycles of (±R)CHOP. For patients 
enrolled retrospectively, eligibility was assessed on the profile at the time treatment was 
planned, not on outcome or number of delivered cycles. 
The study was conducted in accordance with the principles of the Declaration of Helsinki and 
approved by ethics committees and institutional review boards at all participating centers. 
Written informed consent was obtained from all patients where required. 
The full analysis set (FAS) included all patients who started at least one cycle of (±R)CHOP 
and provided data. Anemia-related outcomes included ESA exposure and change in Hb 
concentration after receiving ESA treatment. In addition, requirement for blood transfusion 
was evaluated in a subset of patients who were enrolled in the study for at least 29 days 
(including the day of ESA initiation) after starting ESA treatment. 
The statistical analysis was descriptive in nature. Categorical data were summarized by the 
number and percentage of patients in each category, with summary statistics generated for 
continuous data. For patients who received one or more transfusions, data on Hb 
concentrations were disregarded for 28 days post-transfusion. 
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Results 
Of 1829 patients in the FAS, 404 (22%) received an ESA, of whom approximately half 
(n=207) received DA and formed the population for this analysis. Of the 207 patients who 
received DA, 32 (15%) were also participating in another clinical trial. Baseline 
characteristics have been reported previously [7]. In brief, mean (±standard deviation [SD]) 
age was 63.8±12.8 years and 52% of patients were female. Most patients had diffuse large B-
cell lymphomas (68%) and Eastern Cooperative Oncology Group performance statuses of 0–
2 (91%). Ann Arbor stage was I–III in 43% of patients and IV in 57%. Almost all patients 
(96%) had no bone marrow involvement. Most patients (67%) received R-CHOP-21, with 
27% receiving R-CHOP-14, 4% receiving CHOP-21, and 2% receiving CHOP-14. Most 
patients (77%) received six or eight cycles of chemotherapy. 
For most patients, the reason for initiating DA, as specified by the treating physician (more 
than one reason could be specified), was a low or declining Hb concentration (n=167; 81%) 
and/or to reduce the risk of chemotherapy-induced anemia (n=45; 22%). Other reasons 
included evidence-based guidelines (n=7; 3%) and other anemia-related symptoms (n=1; 
0.5%). The mean (±SD) duration of DA exposure was 8.8±6.9 weeks and the mean number 
of doses was 5.1±4.6. Patients made an average of six clinic visits per month, of which two 
visits, on average, were for DA treatment only (Table 1). Overall, 48 patients (23%) had 
chemotherapy and DA treatment synchronized more than 75% of the time. 
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Table 1. Clinic visits and DA synchronization with chemotherapy 
 Patients receiving DA 
(n=207) 
No. clinic visits per month 
 Mean±SD 
 Range 
 
6.0±4.1 
1–19 
No. clinic visits for DA alone 
 Mean±SD 
 n (%) 
 0 
 1–2 
 3–9 
 ≥10 
 
1.8±2.9 
 
95 (46) 
65 (31) 
39 (19) 
8 (4) 
Percentage of DA administrations synchronized  
with chemotherapy visits, n (%) 
 100% 
 75 to <100% 
 50 to <75% 
 25 to <50% 
 >0 to <25% 
 0 
 
 
40 (19) 
8 (4) 
11 (5) 
26 (13) 
92 (44) 
30 (14) 
DA, darbepoetin alfa; SD, standard deviation 
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At the time of DA initiation, mean (±SD) Hb concentration in 201 patients for whom data 
were available was 10.1±1.3 g/dL (range 5.9–13.7 g/dL). Of these, most (n=139; 67%) had 
Hb concentrations of 9–11 g/dL at the time of initiation, with 29 patients (14%) and 33 
patients (16%) having Hb concentrations <9 or >11 g/dL, respectively. Of the 89 patients 
with Hb concentrations <10 g/dL at DA initiation and still receiving DA treatment at 5 weeks 
after initiation, 38 (crude percentage, 43%; Kaplan–Meier percentage, 92% [95% confidence 
interval [CI]: 78–105%]) achieved Hb concentrations 10–12 g/dL between week 5 after DA 
initiation and the end of the treatment period (Table 2). Overall, 27% of patients receiving 
DA experienced an excess rate of rise, defined as a change in Hb concentration ≥1.0 g/dL in 
14 days, ≥1.5 g/dL in 21 days, or ≥2.0 g/dL in 28 days. 
Between DA initiation and end of treatment, 57 patients (crude percentage, 28%; Kaplan–
Meier percentage, 33% [95% CI: 25–41%]) required a red-blood-cell transfusion, with 33% 
of all transfusions given in the first 2 weeks after DA initiation. Of the 57 patients who 
required a transfusion, 3 (5%) required 1 unit, 23 (40%) required 2–3 units, 15 (26%) 
required 4–5 units, and 16 (28%) required ≥6 units. Overall, the mean (±SD) number of units 
was 4.2±2.8. The most common Hb ranges at the time of transfusion were 9–<10 g/dL (n=19; 
33%) and 10–<11 g/dL (n=15; 26%). The transfusion subset (ie patients who spent ≥29 days 
in the study after initiating ESA treatment) included 176 patients, of whom 31 (crude 
percentage, 18%; Kaplan–Meier percentage, 29% [95% CI: 17–41%]) required a transfusion 
between week 5 after DA initiation and end of treatment. 
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Table 2. Achievement of specified Hb concentrations from 5 weeks after initiation of DA 
treatment to end of the DA treatment period* 
Patients with Hb <10 g/dL at ESA initiation and who remained in study at week 5 (n=89) 
Achieved Hb ≥10 g/dL 
 n 
 Crude percentage 
 KM percentage† (95% CI) 
 
46 
52 
95 (87–103) 
Achieved Hb 10–12 g/dL 
 n 
 Crude percentage 
 KM percentage† (95% CI) 
 
38 
43 
92 (78–105) 
Patients with Hb <11 g/dL at ESA initiation and who remained in study at week 5 (n=155) 
Achieved Hb ≥11 g/dL 
 n 
 Crude percentage 
 KM percentage† (95% CI) 
 
68 
44 
88 (74–101) 
Patients with Hb <12 g/dL at ESA initiation and who remained in study at week 5 (n=182) 
Achieved Hb ≥12 g/dL 
 n 
 Crude percentage 
 KM percentage† (95% CI) 
 
48 
26 
62 (41–82) 
Achieved Hb 12–13 g/dL 
 n 
 Crude percentage 
 KM percentage† (95% CI) 
 
35 
19 
42 (26–59) 
CI, confidence interval; KM, Kaplan–Meier 
Hb values within 28 days after red-blood-cell transfusions are excluded 
*Defined as date of ending DA treatment +17 days for patients dosed every 7 days and 
+31 days for patients dosed every 21 days 
†The Kaplan–Meier percentage accounts for study drop-outs and is, therefore, larger than the 
crude percentage based on the number of patients in the study at week 5 
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Discussion 
Overall, the results of this observational study show that DA provided good control of Hb 
concentrations for most patients, with a quarter of patients experiencing an excess rate of Hb 
rise. Hb concentration at the time of initiation was in the range 9–11 g/dL in 67% of patients, 
which is consistent with the guidelines of the EORTC at the time of the study [4,5,9]. Thus, 
one-third of patients started DA at concentrations outside the recommended range, including 
14% who initiated DA at concentrations below 9 g/dL.  
The summaries of Hb concentration at DA initiation in this analysis were based on all 
patients within the DA-treated set and cannot, therefore, be compared directly with the 
published data for the ESA-treated study population, for which percentages were based on the 
number of patients with available Hb results. The results of patients receiving DA did, 
however, appear broadly similar to those of patients receiving other ESAs in the overall study 
population, in which 65% of patients had Hb concentrations of 9–11 g/dL when ESA 
treatment was initiated, and where 89% (95% CI: 78–101; Kaplan–Meier percentage) of 
patients achieved Hb concentrations 10–12 g/dL between week 5 and the end of the treatment 
period [7]. The results of the present analysis are also consistent with older observational 
studies of ESA treatment [10,11]. As IMPACT NHL was an observational study, and 
included patients enrolled retrospectively, the results should be interpreted with the 
appropriate caution.  
One issue that deserves consideration in the light of our data, in which some patients 
experienced Hb overshoot and others began DA treatment at a non-indicated baseline Hb 
level, is the potential for excess disease progression and/or mortality, as raised in previous 
publications [12,13]. More recent studies, however, contradict this hypothesis. For example, 
in a pooled analysis of  randomized, double-blind, placebo-controlled trials in patients with 
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chemotherapy-induced anemia receiving DA or placebo (n=2122), DA had no impact on 
mortality, progression-free survival or disease progression [14]. Similarly, three meta-
analyses – one of studies in patients with lymphoproliferative malignancies [15], one in 
patients with lung cancer [16] and one broader analysis of oncology studies [17] – found no 
effect of ESAs on survival or disease progression. 
In conclusion, this observational study found that DA was initiated most frequently in 
response to low or declining Hb concentrations. Hb concentration at the time of initiation was 
consistent with current EORTC guidelines in two-thirds of patients. Most patients who had 
Hb <10 g/dL when DA was initiated achieved stable target Hb concentrations of 10–12 g/dL 
by the end of the treatment period. Overall, we believe that the results of this analysis provide 
useful information for clinicians considering DA treatment for those patients with NHL who 
are receiving chemotherapy and have developed anemia. 
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